title: HLA-A*2402-restricted HIV-1-specific cytotoxic T lymphocytes and escape mutation after ART with structured treatment interruptions.
abstract: Although a limited duration of immune activation of structured treatment interruptions (STIs) has been reported, the immune escape mechanism during STIs remains obscure. We therefore investigated the role of three immunodominant cytotoxic T lymphocyte (epitopes) in 12 HLA-A*2402-positive patients participating longitudinally during the clinical study of early antiretroviral treatment (ART) with five series of structured treatment interruptions (STIs). The frequency of HLA-A*2402-restricted CTLs varied widely and a sustained CTL response was rarely noted. However, a Y-to-F substitution at the second position in an immunodominant CTL epitope Nef138-10 (Nef138-2F), which was previously demonstrated as escape mutation, was frequently detected in seven patients primarily and emerged in the remaining five patients thereafter, and the existence of escape mutations was correlated with high pVL levels early in the clinical course. These findings suggest that escape mutation in the immunodominant CTL epitope may be one of the mechanisms to limit HIV-1-specific immune control in STIs.
authors.affiliation: AIDS Clinical Center, International Medical Center of Japan, 1-21-1 Toyama, Shinjuku, Tokyo 162-8655, Japan. jtanuma@imcj.hosp.go.jp
authors.forename: Junko
authors.initials: J
authors.lastname: Tanuma
authors.forename: Mamoru
authors.initials: M
authors.lastname: Fujiwara
authors.forename: Katsuji
authors.initials: K
authors.lastname: Teruya
authors.forename: Saori
authors.initials: S
authors.lastname: Matsuoka
authors.forename: Hikaru
authors.initials: H
authors.lastname: Yamanaka
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Gatanaga
authors.forename: Natsuo
authors.initials: N
authors.lastname: Tachikawa
authors.forename: Yoshimi
authors.initials: Y
authors.lastname: Kikuchi
authors.forename: Masafumi
authors.initials: M
authors.lastname: Takiguchi
authors.forename: Shinichi
authors.initials: S
authors.lastname: Oka
mesh_terms: D044966:Anti-Retroviral Agents / Q000494:pharmacology* / Q000627:therapeutic use; D000939:Epitopes / Q000235:genetics / Q000276:immunology; D015658:HIV Infections / Q000097:blood / Q000276:immunology* / Q000821:virology; D015497:HIV-1 / Q000276:immunology*; D015234:HLA-A Antigens / Q000276:immunology*; D059871:HLA-A24 Antigen; D006801:Humans; D009154:Mutation; D011446:Prospective Studies; D013602:T-Lymphocytes, Cytotoxic / Q000737:chemistry* / Q000276:immunology*
chemical_list: D044966:Anti-Retroviral Agents; D000939:Epitopes; D015234:HLA-A Antigens; C438506:HLA-A*24:02 antigen; D059871:HLA-A24 Antigen